Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA.
Urol Clin North Am. 2012 Nov;39(4):573-81. doi: 10.1016/j.ucl.2012.07.012.
This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.
本文回顾了转移性去势抵抗性前列腺癌(mCRPC)化疗的初步经验,并概述了该领域正在进行的一些临床试验。此外,作者还概述了回顾性分析随机试验中接受紫杉烷类化疗的患者的结局的现有知识。这些数据旨在为医生和患者提供关于 mCRPC 男性结局的一般概念,以促进临床决策以及临床试验的设计和评估。